Actively Recruiting
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
Led by Sunnybrook Health Sciences Centre · Updated on 2026-01-29
112
Participants Needed
2
Research Sites
573 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevalence of congestive heart failure (CHF) in Canada is high, representing one of the health care system's most expensive diagnoses. Despite major advances in medicine, the mortality and morbidity from CHF remains great. Currently, magnetic resonance imaging (MRI) is used for non-invasive imaging of the cardiovascular system to enable the structure and anatomy of the organ to be visualized. However, current MRI methods have limitations when assessing and aiding in the management of CHF. A new imaging method has recently been developed that is showing great promise as a tool in the management of patients with CHF. Rapid imaging of biochemical reactions within myocytes using MRI has recently become possible through the use of the Dynamic Nuclear Polarization (DNP) and dissolution method. DNP-dissolution results in an intravenous contrast agent that is "hyperpolarized", producing a magnetic signal that is enhanced by up to 100,000 fold. The particular agent is carbon-13 labelled pyruvate. In this study, we demonstrate the first 13C-metabolic images of the human heart, along with the required hardware and data acquisition methods.
CONDITIONS
Official Title
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written consent to participate
- Age 19 to 50 years for Arm 1 participants
- Age 30 to 75 years for Arm 2 participants
- Participants in Group 2A and 2E have left-ventricular hypertrophy
- Participants in Group 2B and 2F have diagnosed hypertrophic cardiomyopathy
- Participants in Group 2C and 2G are stable outpatients with NYHA class 1-3 heart failure and elevated left ventricular mass
- Participants in Group 2D and 2H are stable patients with type 2 diabetes mellitus with HbA1c between 6.5% and 9% on oral hypoglycemic agents
You will not qualify if you...
- Contraindications to MRI or MRI contrast agents
- Hemoglobin level less than or equal to 9.0 gm/dL (Group 2 only)
- Glomerular filtration rate less than 30 ml/min/1.73m2 (Group 2 only)
- Any condition with a life expectancy less than 1 year
- Medically diagnosed claustrophobia
- Use of another investigational medicinal product from 1 month before to 1 month after inclusion
- Body mass index less than 18.5 or greater than 32
- Medically diagnosed heart disease for Group 1 participants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Actively Recruiting
2
St. Michael's Hospital
Toronto, Ontario, Canada
Not Yet Recruiting
Research Team
N
Norberto Garcia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here